Molbio Diagnostics Limited witnessed a significant change in its shareholding pattern following the disposal of 30,00,000 equity shares by India Business Excellence Fund III on September 23, 2026. The transaction was executed through the open market and resulted in the fund breaching the 2% threshold specified in Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The seller, India Business Excellence Fund III, is a scheme of Business Excellence Trust III and is not part of the promoter or promoter group. The disclosure was filed with BSE Limited and National Stock Exchange of India Limited on September 24, 2026, by MO Alternate Investment Advisors Private Limited, acting as the investment manager for the fund.

Shareholding Details Before and After Disposal

Prior to the transaction, India Business Excellence Fund III held 11,52,39,996 shares, representing 11.52% of the company's total share capital. Following the sale of 30 lakh shares, the holding decreased to 11,22,39,996 shares, constituting 8.92% of the total diluted share capital.

Regulatory Compliance and Transaction Mode

The disposal triggered a mandatory disclosure under Regulation 29(2) because the aggregate sale crossed the 2% threshold limit for substantial shareholders. The mode of sale was confirmed as an open market transaction. There were no encumbrances such as pledges, liens, or non-disposal undertakings associated with the shares held by the fund prior to the sale.

What the Numbers Show

The transaction highlights a concentrated reduction in institutional holding within a single trading session. By selling exactly 30,00,000 shares, the fund reduced its stake by precisely 2.60 percentage points. This specific volume suggests a planned exit strategy rather than opportunistic trading, as it aligns perfectly with the regulatory threshold breach requiring public disclosure. The remaining 8.92% stake indicates that while the fund has significantly reduced its exposure, it retains a substantial position in Molbio Diagnostics.

Molbio Diagnostics shares worth ₹365.64 crore were flagged by a real-time trade-scanning system after approximately 27,80,549 shares changed hands on BSE at a price of ₹1,315.00 per share.

This is a real-time large-trade signal, not a confirmed block or bulk deal. NSE/BSE publish official block and bulk deal reports only after market close — this trade may or may not appear there.

Large-trade signal details

The following table summarises the parameters of the flagged activity:

The signal reflects a cluster of trades in Molbio Diagnostics shares printed within a short window at or near ₹1,315.00, for a combined value of ₹365.64 crore. The activity was flagged by the system on account of its size and speed and does not, by itself, constitute a confirmed exchange-level event. No buyer, seller, broker, or client identity is known at this stage, as such disclosures are made only by the exchange after market close.

What this is, and isn't: this reflects trade-level activity — a cluster of trades in the stock above, printed within a short window at or near the quoted price, for a combined value as stated. It is generated by our real-time trade-scanning system and is not, by itself, evidence of a block or bulk deal.

A block deal has to be executed in the exchange's dedicated window (8:45–9:00am or 2:05–2:20pm), within a set price band, and above the current minimum order size (₹25 crore). A bulk deal is when one client's total trading in a stock crosses 0.5% of its equity in a single day — confirmed only once every trade that client made is added up.

Both are published by NSE/BSE after trading hours end, typically after 3:30pm — never before. If this trade qualifies as either, it will appear in the exchange's own report later today, not here first.